Fowlicidin-1 (8-26)[T5W, I7R, N11K]

General Information


DRACP ID  DRACP03872

Peptide Name   Fowlicidin-1 (8-26)[T5W, I7R, N11K]

Sequence  LVIRWVRAGYKLYRAIKKK

Sequence Length  19

UniProt ID  Q6QLQ5 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C113H189N33O22

Absent amino acids  CDEFHMNPQST

Common amino acids  K

Mass  268320

Pl  11.75

Basic residues  7

Acidic residues  0

Hydrophobic residues  9

Net charge  7

Boman Index  -3259

Hydrophobicity  -23.16

Aliphatic Index  123.16

Half Life 
  Mammalian: 100 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  8480

Absorbance 280nm  471.11

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 31473417

Title  The design of a cell-selective fowlicidin-1-derived peptide with both antimicrobial and anti-inflammatory activities

Doi Not available

Year  2019

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  13895

DRACP is developed by Dr.Zheng's team.